0001193125-22-220557.txt : 20220815 0001193125-22-220557.hdr.sgml : 20220815 20220815071834 ACCESSION NUMBER: 0001193125-22-220557 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220815 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220815 DATE AS OF CHANGE: 20220815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 880488686 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32335 FILM NUMBER: 221162309 BUSINESS ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 BUSINESS PHONE: (858) 794-8889 MAIL ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121-1345 FORMER COMPANY: FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC DATE OF NAME CHANGE: 20040312 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 8-K 1 d295619d8k.htm 8-K 8-K
false 0001159036 0001159036 2022-08-15 2022-08-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 15, 2022

 

 

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Commission File Number 001-32335

 

Delaware   88-0488686

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

11388 Sorrento Valley Road  
San Diego  
California   92121
(Address of principal executive offices)   (Zip Code)

(858) 794-8889

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   HALO   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01. Other Events.

On August 15, 2022, Halozyme Therapeutics, Inc. (the “Company”) issued a press release announcing that it proposes to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of convertible senior notes due 2028 (the “Convertible Notes”). The Company expects to grant to the initial purchasers an option to purchase up to an additional $75.0 million aggregate principal amount of Convertible Notes. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.		   

Description

99.1    Press release dated August 15, 2022
104    Inline XBRL for the cover page of this Current Report on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    HALOZYME THERAPEUTICS, INC.
August 15, 2022     By:  

/s/ Mark Snyder

    Name:   Mark Snyder, Esq.
    Title:   Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
 EX-99.1 2 d295619dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

FOR IMMEDIATE RELEASE

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million

of Convertible Senior Notes due 2028

The Company plans to purchase up to $200 million worth of shares concurrently with, or shortly after, the pricing of the offering

SAN DIEGO, CA (August 15, 2022) — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”), a leader in converting IV biologics to subcutaneous delivery and autoinjector devices, today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2028 (the “Convertible Notes”). The Convertible Notes are to be offered and sold to “qualified institutional buyers” pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Company also expects to grant a 13-day option to the initial purchasers to purchase up to an additional $75 million aggregate principal amount of Convertible Notes.

The Convertible Notes will be senior, unsecured obligations of the Company and will accrue interest payable semi-annually in arrears. The Convertible Notes will mature on August 15, 2028, unless earlier redeemed, repurchased or converted in accordance with their terms prior to such date. Prior to the close of business on the business day immediately preceding February 15, 2028, the Convertible Notes will be convertible only upon the satisfaction of certain conditions and during certain periods, and on and after February 15, 2028, at any time prior to the close of business on the second scheduled trading day immediately preceding the maturity date, the Convertible Notes will be convertible regardless of these conditions. The Company will settle conversions in cash and, if applicable, shares of the Company’s common stock. The initial conversion rate, interest rate and other terms of the Convertible Notes will be determined at the time of pricing in negotiations with the initial purchasers of the Convertible Notes.

In connection with the offering, the Company intends to enter into privately negotiated capped call transactions with option counterparties that may include one or more of the initial purchasers and/or their affiliates and/or other financial institutions. If the initial purchasers exercise their option to purchase additional notes, the Company may enter into additional capped call transactions with the option counterparties. The capped call transactions are generally expected to reduce potential dilution to the Company’s common stock upon conversion of the convertible notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be.

The Company has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties and/or their affiliates (i) expect to purchase shares of the Company’s common stock and/or enter into derivative transactions with respect to the Company’s common stock concurrently with, or shortly after, the pricing of the Convertible Notes and (ii) may modify their hedge positions by entering into or unwinding derivative transactions with respect to the Company’s common stock and/or purchasing or selling the Company’s common stock or other securities of the Company in secondary market transactions following the pricing of the Convertible Notes and prior to the maturity of the Convertible Notes. These activities could have the effect of increasing, or preventing a decline in, the market price of the Company’s common stock concurrently with, or shortly following, the pricing of the Convertible Notes. The effect, if any, of these activities, including the direction or magnitude, on the market price of the Company’s common stock will depend on a variety of factors, including market conditions, and cannot be ascertained at this time. Any of these activities could, however, adversely affect the market price of the Company’s common stock.

The Company expects to use a portion of net proceeds of the offering to fund the cost of entering into the capped call transactions. The Company also expects to use a portion of the net proceeds of the offering to enter into privately negotiated agreements with certain holders of its outstanding 1.25% convertible senior notes due 2024 (the “Existing Convertible Notes”) to exchange their Existing Convertible Notes for a combination of cash and shares of its common stock through privately negotiated transactions entered into concurrently with or shortly after the pricing of the proposed offering (the “Note Repurchases”).

LOGO

 

In parallel to this transaction, the Company expects to use a portion of the net proceeds of the offering for the repurchase of shares of its common stock (the “Share Repurchases”) up to $200 million, concurrently with, or shortly after, the pricing of the offering in privately negotiated transactions or otherwise, which may be effected through one or more of the initial purchasers or any affiliate thereof.

The Share Repurchases, if consummated in full, would represent an increase of $100 million of the previously planned share repurchases to be made in 2022 under the Company’s ongoing three-year $750 million share repurchase program, which was commenced and previously announced in 2021.

Further, the Company expects to use a portion of the net proceeds of the offering to repay all of its outstanding $250 million term loan facility due 2026. The Company intends to use the remainder of the net proceeds from the offering for general corporate purposes, including other repurchases of the Company’s common stock from time to time under the existing stock repurchase program, working capital, capital expenditures, potential acquisitions and strategic transactions. If the initial purchasers exercise their option to purchase additional notes, the Company intends to use a portion of the net proceeds from the sale of additional notes to fund the cost of entering into additional capped call transactions.

The Note Repurchases and Share Repurchases could increase (or reduce the size of any decrease in) the market price of Halozyme common stock or the Convertible Notes. We also expect that some existing noteholders may purchase or sell shares of the Company’s common stock in the market to hedge their exposure in connection with these transactions. The Note Repurchases, Share Repurchases and any associated hedging by holders could affect the market price of the Company’s common stock prior to, concurrently with or shortly after the pricing of the Convertible Notes and could also result in a higher effective conversion price for the Convertible Notes.

This press release is neither an offer to sell nor a solicitation of an offer to buy the Convertible Notes or the shares of the Company’s common stock issuable upon conversion of the Convertible Notes, if any, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offer of these securities will be made only by means of a private offering memorandum.

The offer and sale of the Convertible Notes and the shares of the Company’s common stock issuable upon conversion of the Convertible Notes, if any, have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Forward-looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the planned offering. Words such as “anticipates,” “estimates,” “expects,” “projects,” “forecasts,” “intends,” “plans,” “will,” “believes” and words and terms of similar substance used in connection with any discussion identify forward-looking statements. These forward-looking statements are based on management’s current expectations and beliefs about future events and are inherently susceptible to uncertainty and changes in circumstances. Except as required by law, the Company is under no obligation to, and expressly disclaims any obligation to, update or alter any forward-looking statements whether as a result of such changes, new information, subsequent events or otherwise. With respect to the planned offering, such uncertainties and circumstances include whether the Company will offer the notes or consummate the offering; and the anticipated terms of the notes and the use of the net proceeds from the offering. Various factors could also adversely affect the Company’s operations, business or financial results in the future and cause the Company’s actual results to differ materially from those contained in the forward-looking statements, including those factors discussed in detail in the “Risk Factors” sections contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022, which are filed with the Securities and Exchange Commission.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme’s commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 600,000 patient lives in post-marketing use in five commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.

LOGO

 

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED®, TLANDO™ and NOCDURNA® and partnered commercial products and ongoing product development programs with industry leading pharmaceutical companies including Teva Pharmaceutical, Covis Pharma, Pfizer and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

EX-101.SCH 3 halo-20220815.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 halo-20220815_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 halo-20220815_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g295619g0810030609698.jpg GRAPHIC begin 644 g295619g0810030609698.jpg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htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Aug. 15, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001159036
Document Type 8-K
Document Period End Date Aug. 15, 2022
Entity Registrant Name HALOZYME THERAPEUTICS, INC.
Entity File Number 001-32335
Entity Incorporation State Country Code DE
Entity Tax Identification Number 88-0488686
Entity Address, Address Line One 11388 Sorrento Valley Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 794-8889
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol HALO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d295619d8k_htm.xml IDEA: XBRL DOCUMENT 0001159036 2022-08-15 2022-08-15 false 0001159036 8-K 2022-08-15 HALOZYME THERAPEUTICS, INC. 001-32335 DE 88-0488686 11388 Sorrento Valley Road San Diego CA 92121 (858) 794-8889 false false false false Common Stock, $0.001 par value HALO NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d295619d8k.htm d295619dex991.htm halo-20220815.xsd halo-20220815_lab.xml halo-20220815_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d295619d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d295619d8k.htm" ] }, "labelLink": { "local": [ "halo-20220815_lab.xml" ] }, "presentationLink": { "local": [ "halo-20220815_pre.xml" ] }, "schema": { "local": [ "halo-20220815.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "halo", "nsuri": "http://www.halozyme.com/20220815", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d295619d8k.htm", "contextRef": "duration_2022-08-15_to_2022-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d295619d8k.htm", "contextRef": "duration_2022-08-15_to_2022-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.halozyme.com//20220815/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-22-220557-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-220557-xbrl.zip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